Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Fulvestrant 127Trastuzumab 117Paclitaxel 113Letrozole 109pembrolizumab 81palbociclib 76pertuzumab 75Capecitabine 74Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 65exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 57Specimen Handling 51Surveys and Questionnaires 50Radiotherapy 50Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 42olaparib 40Standard of Care 36Biopsy 33sacituzumab govitecan 32130-nm albumin-bound paclitaxel 32Exercise 30Doxorubicin 30eribulin 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × 1 year × Clear all
NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

University of Washington

Phase 1/2 Recruiting
22 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡